PRESENTED BY

Mahima Malviya
Gayatri Jadhav
 INTRODUCTION
1. It is an Indian biopharmaceutical company based in
Bangalore, India.
2. The company manufactures generic active
pharmaceutical ingredients that are sold in over 120
countries across the globe.
3. It also manufactures novel biologics, and antibodies.
4 .Subsidiary company-: Syngene International
Company
5. Employ strength -: Biocon and Syngene together
employ about 9200 personnel
 History
1. Biocon was founded in 1978 with ₹10,000 (US$150) as
the initial capital, failing to find any financial institution
for investment. The operations began out of the garage
of a rented house with two employees.
2. Biocon’s first product to go to market was PAPAIN, an
enzyme found in papaya which is used to prevent beer
from turning hazy.
3. Until 1983, the company blended enzymes and
supplied them to brewing, textiles, bio-fuels, animal feed
and other such industries across the world.
4. In 1989, the Irish BIOCON was acquired by Unilever.
5. John Shaw, the Scotsman whom Kiran Mazumdar–
Shaw had married in 1998, used his savings to reclaim
the entire Biocon stake from Unilever.
 SWOT Analysis
Strength Weakness
• Cheap labour in Indian labour • Proper infrastructure
market underdeveloped

• Comparatively less production • Unable to purchase

cost expensive equipment

• Availability skilled labour • Separate education and

research work
• Patients are treatment naïve

• Growing GDP, which helps

common people spend more
on medicine
 SWOT Analysis
Opportunities Threats
• Great exposure to global • Skilled people moving out of
market country

• Tax reduction by government • Highly competitive market

with new investments
• The success of new ventures
• The success of subsidiary
• Demand in global sphere unit than parent unit
increasing
• Inflation of wage

• Regulatory acts of
government

• Foreign groups are

introduced in Indian market
 FINANCIAL ANALYSIS
1.For the Financial Year 2015-16
Equity and Liabilities-: (a) Share capital- 100crore (b) Reserve and surplus-3956crore
(c) Non-current liabilities- 2487crore (d) Current liabilities- 1628crore
Assets-: (a) Non-current assets- 4489crore (b) Current assets- 3993crore
Total Revenue- 3570crore Net Profit- 896crore
2. For the Financial Year 2014-15
Equity and Liabilities-: (a) Share capital- 100crore (b) Reserve and surplus- Rs
31622m (c) Current liabilities- Rs15974m (d) Long term debts- Rs 7671m
Assets-: (a) Non-current assets- Rs 34169m (b) Current assets- Rs 24750m
Total Revenue- Rs 31429m Net Profit- Rs 4974m
 FINANCIAL ANALYSIS
3. For the Financial year 2013-14

Equity and Liabilities-: (a) Share capital- 100crore (b) Reserve and surplus- Rs
27047m (c) Current Liabilities- Rs 13796m (d) Long term debt- Rs6062m

Assets-: (a) Non-current assets- Rs 27308m (b) Current assets- Rs 26388m

Total Revenue- Rs 29332m Net Profit- Rs 4138m

Revenue Analysis
 BIOCON VS CIPLA
Biocon Cipla
 Mergers and Acquisition
•Syngene International Pvt Ltd

•Clinigene

•BBPL

•Biocon-AxiCorp

•NeoBiocon

•Biocon and Amylin

•Biocon and IATRICa

•Biocon and Mylan

•Biocon and Optimer

Thank you